PMID- 34046975
OWN - NLM
STAT- MEDLINE
DCOM- 20220314
LR  - 20220314
IS  - 1468-1293 (Electronic)
IS  - 1464-2662 (Linking)
VI  - 22
IP  - 8
DP  - 2021 Sep
TI  - Integrase strand transfer inhibitor treatment does not increase the incidence of 
      immune reconstitution inflammatory syndrome in HIV-infected Koreans.
PG  - 705-714
LID - 10.1111/hiv.13117 [doi]
AB  - OBJECTIVES: Immune reconstitution inflammatory syndrome (IRIS) is a major concern 
      when starting antiretroviral therapy (ART) in patients with advanced HIV 
      infection. The aim of this study was to determine the incidence and risk factors 
      of IRIS in HIV-infected Koreans initiating ART, and whether integrase strand 
      transfer inhibitor (INSTI) treatment increases the risk of IRIS. METHODS: This 
      retrospective analysis included adults living with HIV, seen at four 
      university-affiliated hospitals in South Korea, who were naive to ART and had a 
      CD4 T-cell count < 200 cells/muL between January 2004 and May 2019. IRIS was 
      determined through a medical record review within 6 months of ART initiation. 
      Propensity score-matched case-control study between the non-INSTI and INSTI 
      groups was performed. RESULTS: The study included 501 patients; 192 were assigned 
      to the INSTI group, who started ART based on INSTIs as the initial treatment. 
      There were opportunistic infections (OIs) in 253 (50.5%) cases before ART 
      initiation. The three most common OIs were Pneumocystis jirovecii pneumonia, 
      candidiasis and tuberculosis (TB). We identified 47 cases of IRIS; TB-IRIS was 
      the most common type. The incidence of IRIS within 6 months of ART initiation was 
      9.4%, and there were no significant differences in baseline characteristics and 
      incidence of IRIS between the matched groups. The risk factors for IRIS were 
      pre-ART CD4 T-cell count (< 30 cells/muL), higher pre-ART viral load (>/= 75 000 
      copies/mL), and TB-OI. CONCLUSIONS: The incidence of IRIS was 9.4% in Korean HIV 
      patients. The INSTI regimen was not related to IRIS occurrence.
CI  - (c) 2021 British HIV Association.
FAU - Kim, J
AU  - Kim J
AD  - Department of Infectious Diseases, Chonnam National University Medical School, 
      Chonnam National University Hospital, Gwangju, Korea.
FAU - Nam, H-J
AU  - Nam HJ
AD  - Department of Infectious Diseases, Chonnam National University Medical School, 
      Chonnam National University Hospital, Gwangju, Korea.
FAU - Kang, S-J
AU  - Kang SJ
AD  - Department of Infectious Diseases, Chonnam National University Medical School, 
      Chonnam National University Hospital, Gwangju, Korea.
FAU - Jung, S-I
AU  - Jung SI
AD  - Department of Infectious Diseases, Chonnam National University Medical School, 
      Chonnam National University Hospital, Gwangju, Korea.
FAU - Hwang, C H
AU  - Hwang CH
AD  - Biomedical Research Institute, Chonnam National University Hospital, Gwangju, 
      Korea.
FAU - Kim, Y-S
AU  - Kim YS
AD  - Department of Internal Medicine, Chungnam National University Medical School, 
      Deajeon, Korea.
FAU - Chang, H-H
AU  - Chang HH
AD  - Department of Internal Medicine, Kyungpook National University School of 
      Medicine, Daegu, Korea.
FAU - Kim, S-W
AU  - Kim SW
AD  - Department of Internal Medicine, Kyungpook National University School of 
      Medicine, Daegu, Korea.
FAU - Park, K-Hwa
AU  - Park KH
AD  - Department of Infectious Diseases, Chonnam National University Medical School, 
      Chonnam National University Hospital, Gwangju, Korea.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20210528
PL  - England
TA  - HIV Med
JT  - HIV medicine
JID - 100897392
RN  - EC 2.7.7.- (Integrases)
SB  - IM
MH  - Adult
MH  - Case-Control Studies
MH  - *HIV Infections/complications/drug therapy/epidemiology
MH  - Humans
MH  - *Immune Reconstitution Inflammatory Syndrome/chemically induced/epidemiology
MH  - Incidence
MH  - Integrases
MH  - Retrospective Studies
OTO - NOTNLM
OT  - HIV
OT  - antiretroviral therapy
OT  - immune reconstitution inflammatory syndrome
OT  - integrase strand transfer inhibitor
OT  - tuberculosis
EDAT- 2021/05/29 06:00
MHDA- 2022/03/15 06:00
CRDT- 2021/05/28 07:50
PHST- 2021/03/30 00:00 [accepted]
PHST- 2021/05/29 06:00 [pubmed]
PHST- 2022/03/15 06:00 [medline]
PHST- 2021/05/28 07:50 [entrez]
AID - 10.1111/hiv.13117 [doi]
PST - ppublish
SO  - HIV Med. 2021 Sep;22(8):705-714. doi: 10.1111/hiv.13117. Epub 2021 May 28.